CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Adam J LambleLisa Eidenschink BrodersenTodd A AlonzoJim WangLaura PardoLillian SungTodd M CooperEdward Anders KolbRichard AplencSarah K TasianMichael R LokenSoheil MeshinchiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
CD123 is strongly associated with disease-relevant cytogenetic and molecular alterations in childhood AML. CD123 is a critical biomarker and promising immunotherapeutic target for children with relapsed or refractory AML, given its prevalent expression and enrichment in patients with high-risk genetic alterations and inferior clinical outcomes with conventional therapy.
Keyphrases
- acute myeloid leukemia
- poor prognosis
- allogeneic hematopoietic stem cell transplantation
- young adults
- palliative care
- nk cells
- binding protein
- acute lymphoblastic leukemia
- long non coding rna
- gene expression
- genome wide
- stem cells
- childhood cancer
- diffuse large b cell lymphoma
- bone marrow
- copy number
- hodgkin lymphoma